Disinfection Cap Market Size, Share, Opportunities, And Trends By Type (Double Cap System, Single Cap System), By Distributor (Retail, Non-retail), By End-Use (Hospitals, Clinics, Others), And By Geography - Forecasts From 2023 To 2028

The disinfection cap market is estimated to grow at a CAGR of 8.03% during the forecast period.

Disinfectant caps serve as an extra layer of defense against microbial contamination to lower the incidence of illnesses linked to medical equipment. The growing prevalence of healthcare-acquired infections and cancer cases are major growth drivers in the disinfection cap market. Moreover, the increasing emphasis on infection control and rising awareness coupled with enhanced product launches are further expected to bolster the disinfection cap market.

Growing Prevalence of Healthcare-acquired Infections (HAIs)

The growing prevalence of HAIs is a major growth driver of the disinfection cap market. According to the WHO, seven patients in high-income countries and 15 patients in low- and middle-income countries out of every 100 patients in acute-care hospitals acquire at least one healthcare-associated infection (HAI) during their hospital stay. On average, one in ten of these patients is expected to die from their HAI as per the WHO. Moreover, the methicillin-resistant Staphylococcus aureus (MRSA) prevalence rate in the USA increased by 14% in 2021 from 2020 and ventilator-associated events (VAE) increased by 12% in 2021 as per the CDC data.

Increasing Cancer Cases

The disinfection cap market is being driven in large part by the rising incidence of cancer as these are used to clean IV connections. For instance, cancer is the leading death cause with more than 10 million worldwide deaths in 2020 according to the WHO. There were around 18 million new cancer cases worldwide in 2020 as per the WCRF. It is important to maintain proper infection control practices during cancer treatment to minimize the risk of infections, as cancer patients may have compromised immune systems. Infections can further complicate the treatment and recovery process therefore disinfection cap is a necessary component for cancer patients.

Rising Healthcare Expenditure

Increasing healthcare expenditure is driving the demand for advanced medical devices and infection control products thereby propelling the disinfection cap market. For instance, global health spending topped $9 trillion in 2020 owing to increased government spending and external aid as per the WHO report. In more than two-thirds of the 50 WHO nations, spending on health system governance and administration increased by an average of 7%. The disinfection cap market benefits from this trend as healthcare providers invest in products that improve patient outcomes and reduce the overall cost burden associated with infections.

Increased Emphasis on Infection Control

Infection control procedures are receiving more attention from healthcare facilities and regulatory agencies. To enhance patient safety and lower the frequency of HAIs, strict restrictions and standards are being introduced. Various programs are being organized by the government institution to reduce infections and HAIs which is aiding the disinfection cap market. For instance, the Emerging Infections Program (EIB) is being run by CDC in collaboration with the US Department of Agriculture, and 10 other US sites. An active laboratory- and population-based surveillance system called ABCs is used to monitor invasive bacterial infections that are significant for public health and is used by EIB. IPC (infection prevention and control) is a realistic, evidence-based strategy developed by the WHO for avoiding infections that might damage patients and healthcare professionals.

Restraints in the Market

The disinfection cap market has experienced growth and development, however, some restraints or challenges can impact its expansion. For example, healthcare professionals and patients' limited knowledge of the advantages and significance of disinfection caps may restrain market expansion. Moreover, due to the variety of medical equipment in the market, maintaining universal compatibility of disinfection caps might be difficult. Additionally, meeting regulatory compliance and obtaining necessary certifications can be time-consuming and expensive, potentially slowing down the disinfection market growth and limiting the entry of new players.

North America is Expected to Grow Significantly

The North American region is anticipated to hold a significant share of the disinfection cap market during the forecasted period. Various factors propelling the market growth in the region are higher HAIs, the presence of a strong healthcare system, robust government programs, and increased awareness about the adverse effects of infection. For instance, over 60,000 more severe sepsis patients are thought to be treated by emergency medical services in the United States each year than heart attack and stroke patients combined as per the Sepsis Alliance. Moreover, the presence of major producers and distributors of disinfection caps in the region such as 3M, B Braun, and ICU Medical is further expected to aid the market expansion.

Major Market Players

• 3M is a multinational conglomerate corporation headquartered in the United States. 3M offers a wide array of products, technologies, and solutions aimed at improving patient outcomes, infection prevention, and overall healthcare efficiency. An alcohol-containing cap called the 3MTM Curos™ Disinfecting Cap for Needleless Connectors twists onto ports to disinfect and shield them.
• ICU Medical offers a diverse portfolio of products and solutions including infusion systems, IV catheters, critical care monitoring, and needleless connectors. SwabCap™ disinfecting cap developed by the company offers individual sterile packaging and the ability to disinfect within 30 seconds for up to 7 days.
• Omnia Health offers various services and solutions to healthcare providers and suppliers including innovative solutions and consultations. I.V. CAPs are designed by the company to be used as a cover over swab-able luer access valves to shield them from potential contamination.
• Becton Dickinson operates across various segments of the healthcare industry, including healthcare institutions, life sciences research, and clinical laboratories. In addition to serving as a physical barrier between line accesses, the BD PureHub™ disinfection cap also serves as a tool for cleaning swabbable needle-free luer connections before access.

 Key Market Developments

• In November 2019, Asset Medical announced its newest product the SwabArt® Disinfection Cap. These are single-use disinfection product that protects from infection through a highly liquid absorbent sponge saturated with 70% of IPA.
• In November 2019, ICU Medical announced the acquisition of Pursuit Vascular, Inc for $75 million to expand its needle-free IV connector and other infection control technologies. The primary product of Pursuit Vascular was the ClearGuard® HD cap which is used for the maintenance of hemodialysis catheters.

Disinfection Cap Market Scope:

 

Report Metric	Details
Growth Rate	CAGR of 8.03% from 2021 to 2028
Base Year	2021
Forecast Period	2023 – 2028
Forecast Unit (Value)	USD Billion
Segments Covered	Type, Distributor, End-Use, and Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	3M Company, Acclima, Inc., ICU Medical, Omnia Health, B. Braun, Becton Dickinson, Merit Pharmaceuticals, Innovamedia, Dr. Schumacher GmbH, Medline
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Type
  • Double Cap System
  • Single Cap System
• By Distributor
  • Retail
  • Non-retail
• By End-Use
  • Hospitals
  • Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. DISINFECTION CAP MARKET, BY TYPE

5.1. Introduction

5.2. Double Cap System

5.3. Single Cap System

6. DISINFECTION CAP MARKET, BY DISTRIBUTOR

6.1. Introduction

6.2. Retail

6.3. Non-retail

7. DISINFECTION CAP MARKET, BY END-USE

7.1. Introduction

7.2. Hospitals

7.3. Clinics

7.4. Others

8. DISINFECTION CAP MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. 3M Company

10.2. Acclima, Inc.

10.3. ICU Medical

10.4. Omnia Health

10.5. B. Braun

10.6. Becton Dickinson

10.7. Merit Pharmaceuticals

10.8. Innovamedia

10.9. Dr. Schumacher GmbH

10.10. Medline

3M Company

Acclima, Inc.

ICU Medical

Omnia Health

B. Braun

Becton Dickinson

Merit Pharmaceuticals

Innovamedia

Dr. Schumacher GmbH

Medline